Ornish et al. — Prostate Cancer Progression Halted by Lifestyle Intervention (2005)
The story
Skip to the verdict ↓A randomized controlled trial of 93 men with biopsy-confirmed prostate cancer found that an intensive lifestyle intervention (vegan diet, exercise, meditation) significantly reduced PSA levels and inhibited cancer cell growth without conventional treatment.
Dean Ornish, Peter Carroll, and colleagues at the University of California, San Francisco conducted the first randomized controlled trial of lifestyle intervention in prostate cancer, published in the *Journal of Urology* in September 2005. The trial enrolled 93 men with biopsy-confirmed prostate cancer who had elected active surveillance (watchful waiting), randomly assigning them to a comprehensive lifestyle program or a comparison group.
The lifestyle intervention included a whole-food vegan diet, 30 minutes of daily walking six days per week, one hour of daily meditation, and nutritional supplementation (soy, fish oil, vitamins E, C, selenium). After one year, PSA decreased 4% in the experimental group versus a 6% increase in controls. Prostate cancer cell growth was inhibited approximately 8-fold more in the experimental group in an in vitro serum assay. None of the men in the experimental group required conventional treatment at one year, versus 6 in the control group.
PSA is a surrogate marker rather than a tumor endpoint. The study did not document biopsy-confirmed tumor regression.
It happened — and nature accounts for it.
Reviewer Notes
Miracles Jar weighs each claim two ways — how extraordinary it would be, and how strong the evidence is.
Assessed by Miracles Jar AI
Scientifically rigorous RCT establishing that lifestyle factors can measurably alter prostate cancer trajectory; does not constitute tumor remission but is a documented non-supernatural cancer modification.
A natural explanation is almost certain.
Why this grades as it does. This is a peer-reviewed, randomized controlled trial published in the Journal of Urology — one of the strongest study designs available. PSA decreased 4% in the experimental group vs. 6% increase in controls; cancer cell growth was inhibited 8x more in the experimental group. No conventional treatment was given to either group during the study period. This is a secular, scientifically rigorous finding. It does not involve supernatural claims. It is included to establish that documented cancer regression can occur through definable biological pathways (dietary and lifestyle-mediated immune and hormonal changes), which is directly relevant to interpreting other healing claims on this site. The main limitation is that PSA reduction and cell growth inhibition in vitro are not equivalent to tumor remission.
This case serves as a scientifically rigorous secular anchor. It demonstrates that documented cancer modification — not merely anecdotal improvement — can occur through biological pathways that are well-defined (dietary, hormonal, immunological). That context matters for evaluating cases in this dataset where "medically inexplicable" is claimed: the baseline of what lifestyle and immune factors can achieve is higher than intuition suggests.
PSA is a surrogate marker, not a tumor endpoint. The study establishes measurable biological modification of cancer trajectory, not remission — it documents control of progression, not elimination.
Evidence weighing:
- Randomized controlled trial design with biopsy-confirmed prostate cancer, 93 participants, 1-year follow-up — the strongest study design in this dataset. Direction: natural; strength: strong. No supernatural mechanism required; results fully explained by known biology.
- PSA decreased 4% (experimental) vs. increased 6% (control); cancer cell growth inhibited 8x more in the lifestyle group. Direction: natural; strength: strong. Statistically significant, clinically meaningful results achieved through lifestyle alone.
- None of the 93 experimental-group men required conventional treatment at 1 year vs. 6 in the control group. Direction: natural; strength: moderate. Clinically significant outcome difference; does not equal tumor remission.
- PSA reduction is a surrogate endpoint — not equivalent to biopsy-confirmed tumor regression or cure. Direction: neutral; strength: moderate. Important limitation; the study documents control of progression, not elimination.
Evidence ledger — what the verdict rests on
Randomized controlled trial design with biopsy-confirmed prostate cancer, 93 participants, 1-year follow-up — the strongest study design in this dataset
No supernatural mechanism required; results fully explained by known biology
PSA decreased 4% (experimental) vs. increased 6% (control); cancer cell growth inhibited 8x more in the lifestyle group
Statistically significant, clinically meaningful results achieved through lifestyle alone
None of the 93 experimental-group men required conventional treatment at 1 year vs. 6 in the control group
Clinically significant outcome difference; does not equal tumor remission
PSA reduction is a surrogate endpoint — not equivalent to biopsy-confirmed tumor regression or cure
Important limitation; the study documents control of progression, not elimination
What would raise the meter: Long-term follow-up documenting permanence, in a condition with a near-zero spontaneous-resolution base rate, would raise the meter.
What would lower it: A documented relapse, or case literature showing the condition fluctuates or remits on its own, would move it down.
How we weigh every claim — the full method, deductions and all →
The natural explanation
The leading natural account for this case is spontaneous remission & the body's own recovery. Read what it explains — and where it stops.
Sources
Tagged by proximity to the event. Primary sources are direct or contemporaneous; tertiary are downstream retellings.
- 1.Primaryacademic
Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Ramsden CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR, "Intensive Lifestyle Changes May Affect the Progression of Prostate Cancer", 2005· no public link
Journal of Urology, 174(3):1065-1070; PMID 16094059; landmark RCT
Cases like this
Nearest on the map — similar in how miraculous they’d be, and how strong the evidence is.